Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma

Chin Med J (Engl). 2021 Jun 16;134(17):2119-2121. doi: 10.1097/CM9.0000000000001511.

Authors

Jia-Ni Wang¹, Quan-Hui Qiao², Xing-Sheng Hu¹, Yu-Tao Liu¹, Zhi-Jie Wang¹, Jian-Chun Duan¹, Yu Feng¹, Hao-Hua Zhu¹

Affiliations

¹ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
² Department of Medical Oncology, Gongyi People's Hospital, Gongyi, Henan 451200, China.

No abstract available

Publication types

Letter

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Neoplasm Staging
Pemetrexed / therapeutic use

Substances

Pemetrexed